Back

Spatial, Temporal, and Molecular Heterogeneity of ADC targets in High-Grade Serous Ovarian Carcinoma

2025-12-05 oncology Title + abstract only
View on medRxiv
Show abstract

BackgroundAntibody-drug conjugates (ADCs) represent a promising therapeutic approach for high-grade serous ovarian carcinoma (HGSOC). Patient selection for ADC therapy depends on tumor target expression, making it essential to characterize molecular, spatial, and temporal heterogeneity. MethodsWe analyzed two HGSOC tissue microarray cohorts: 100 genomically profiled primaries (1,565 cores) and 64 matched cases with paired primary (P), primary disseminated (PD), and recurrent (R) samples (2,395 ...

Predicted journal destinations